Purpose: To compare the therapeutic effects of combination of Olopatidine and Ketorolac vs Olopatidine alone (0.1% Olopatidine hydrochloride and 0.5% Ketorolac tromethamine) in seasonal allergic conjunctivitis (SAC).
Methods: 200 patients with the signs and symptoms of SAC (i.e. hyperaemia, itching, mucus discharge, tearing) were included in this study. In group 1 (100 patients) each patient was treated with “olopatadine and Ketorolac” and group 2 patients were treated with Olopatidine alone. The principle signs and symptoms of SAC (hyperaemia, itching, watering and photophobia) were evaluated at day 0, day 7, day 15 and day 21 by using a 4 point scale. Mean scores of each of the parameters were calculated using paired t test.
Results: When the mean scores of Group 1 (Olopatidine plus Ketorolac) were compared to the scores of Group 2 (Olopatidine only) the mean scores of hyperaemia, itching and watering were found to be lower in Group 1, indicating better therapeutic effectiveness with a significant difference statistically (p<0.05%) on day 7,day 15 and on day 21.
Conclusions: Olopatadine and Ketorolac combination therapy is an effective treatment for seasonal allergic conjunctivitis when compared to Olopatidine alone.